Intensive monitoring of adherence to treatment helps to identify "true" resistant hypertension

Journal of Clinical Hypertension

Volumn 11, Issue 4, 2009, Pages 183-191

  de Souza, Walnéia Aparecida ^a   Sabha, Maricene ^b   de Faveri Favero, Fabrício ^b   Bergsten Mendes, Gun ^b   Yugar Toledo, Juan Carlos ^b   Moreno Jr , Heitor ^b  

^a FEDERAL UNIVERSITY OF ALFENAS   (Brazil)

^b UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE PLUS ENALAPRIL; AMLODIPINE PLUS RAMIPRIL; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROCHLOROTHIAZIDE PLUS LOSARTAN; UNCLASSIFIED DRUG; VISKALDIX;

ADULT; ARTERIAL PRESSURE; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REGIMEN; FEMALE; HEALTH SURVEY; HUMAN; HYPERTENSION; LONG TERM CARE; MALE; PATIENT ATTITUDE; PATIENT COMPLIANCE; PATIENT MONITORING; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT DURATION;

ADULT; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE MONITORING, AMBULATORY; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PROSPECTIVE STUDIES; QUESTIONNAIRES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 65449136694     PISSN: 15246175     EISSN: 17517176     Source Type: Journal    
DOI: 10.1111/j.1751-7176.2009.00102.x     Document Type: Article

References (23)

1. Schroeder K, Fahey T, Ebrahim S. Interventions for improving adherence to treatment in patients with high blood pressure in ambulatory settings. Cochrane Database Syst Rev. 2004;2:CD004804.
2. De Souza WA, Yugar-Toledo JC, Bergsten-Mendes G, et al. Effect of pharmaceutical care on blood pressure control and health-related quality of life in patients with resistant hypertension. Am J Health Syst Pharm. 2007;64:1955-1961.
3. Epstein M. Resistant hypertension: Prevalence and evolving concepts. J Clin Hypertens (Greenwich). 2007;9(1 suppl 1):2-6.
4. Burnier M, Santschi V, Favrat B, et al. Monitoring compliance in resistant hypertension: An important step in patient management. J Hypertens Suppl. 2003;21:S37-S42.
5. Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: Diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for high blood pressure research. Hypertension. 2008;51:1403-1419.
6. Park J, Campese V. Clinical characteristics of resistant hypertension: the importance of compliance and the role of diagnostic evaluation in delineating pathogenesis. J Clin Hypertens. 2007;9(1 suppl 1):7-12.
7. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension. 2003;42:1206-1252.
8. Mancia G, De Backer G, Dominiczak A, et al. ESH/ESC 2007 guidelines for the management of arterial hypertension. Rev Esp Cardiol. 2007;60:968e1-968e94.
9. Moser M, Setaro JF. Clinical practice. Resistant or difficult-to-control hypertension. N Engl J Med. 2006;355:385-392.
10. Sarafidis PA, Bakris GL. State of hypertension management in the United States: Confluence of risk factors and the prevalence of resistant hypertension. J Clin Hypertens. 2008;10:130-139.
11. Pimenta E, Calhoun DA, Oparil S. Mechanisms and treatment of resistant hypertension. Arq Bras Cardiol. 2007;88:683-692.
12. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care. 1986;24:67-74.
13. Litt IF, Cuskey WR. Compliance with medical regimens during adolescence. Pediatr Clin North Am. 1980;27:3-15.
14. Sackett DL, Haynes RB, Gibson ES, et al. Randomised clinical trial of strategies for improving medication compliance in primary hypertension. Lancet. 1975;1:1205-1207.
15. McAlister FA, Lewanczuk RZ, Teo KK. Resistant hypertension: An overview. Can J Cardiol. 1996;12:822-828.
16. Muxfeldt ES, Bloch KV, Nogueira AR, et al. True resistant hypertension: is it possible to be recognized in the office? Am J Hypertens. 2005;18(12 Pt1):1534-1540.
17. Chisholm-Burns MA, Spivey CA. Pharmacoadherence: A new term for a significant problem. Am J Health-Syst Pharm. 2008;65:661-667.
18. Burnier M, Schneider MP, Chioléro A, et al. Electronic compliance monitoring in resistant hypertension: The basis for rational therapeutic decisions. J Hypertens. 2001;19:335-341.
19. Oparil S. Are there meaningful differences in blood pressure control with current antihypertensive agents? Am J Hypertens. 2002;15(1 Pt 2):14S-21S.
20. Oparil S, Calhoun DA. Managing the patient with hard-to-control hypertension. Am Fam Physician. 1998;57:1007-1014.
21. Garg JP, Elliott WJ, Folker A, et al. Resistant hypertension revisited: a comparison of two university-based cohorts. Am J Hypertens. 2005;18(5 Pt 1):619-626.
22. Sica DA. Fixed-dose combination antihypertensive drugs. Do they have a role in rational therapy? Drugs. 1994;48:16-24.
23. Flegal KM, Carroll MD, Ogden CL, et al. Prevalence and trends in obesity among US adults, 1999-2000. J Am Med Assoc. 2002;288:1723-1727.